Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris’ proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm.
Deal Terms and Financials
Under the agreement, Chugai will pay an upfront fee and fund all research activities. After exercising the option, Chugai will be solely responsible for the development, manufacturing, and global commercialization activities. Araris will be eligible for potential milestone payments of approximately USD 780 million, plus royalties on net sales of products, upon Chugai’s achievement of certain development, regulatory, and commercial milestones.
Significance of the Collaboration
This collaboration between Araris Biotech and Chugai Pharmaceutical underscores the growing interest in developing innovative ADCs for oncology. By leveraging Araris’ AraLinQ platform, the partnership aims to accelerate the discovery and development of novel therapies, potentially improving treatment options for patients with various cancers.-Fineline Info & Tech
